Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data

After liver transplantation (LT), the management of recurrent hepatitis C virus (HCV) infections still remains a major challenge. In HCV genotype 1 patients not undergoing transplantation, the introduction of protease inhibitor (PI)–based regimens has increased the sustained virological response rat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver transplantation 2012-12, Vol.18 (12), p.1464-1470
Hauptverfasser:	Werner, Christoph R., Egetemeyr, Daniel P., Lauer, Ulrich M., Nadalin, Silvio, Königsrainer, Alfred, Malek, Nisar P., Berg, Christoph P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Biomarkers - blood Drug Interactions Drug Monitoring Drug Therapy, Combination Feasibility Studies Female Germany Hepacivirus - genetics Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - surgery Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Interferon-alpha - therapeutic use Liver Transplantation - adverse effects Liver Transplantation - immunology Male Middle Aged Oligopeptides - adverse effects Oligopeptides - therapeutic use Pilot Projects Polyethylene Glycols - therapeutic use Recombinant Proteins - therapeutic use Recurrence Retrospective Studies Ribavirin - therapeutic use RNA, Viral - blood Time Factors Treatment Outcome Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!